Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Company Overview - Ovid Therapeutics (OVID) is expected to report a quarterly loss of $0.14 per share, reflecting a year-over-year change of +17.7% [3] - Revenues are anticipated to be $0.07 million, down 53.3% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - The Most Accurate Estimate for Ovid is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.45%, suggesting a bearish sentiment among analysts [10] Historical Performance - In the last reported quarter, Ovid was expected to post a loss of $0.16 per share but actually reported a loss of $0.13, achieving a surprise of +18.75% [12] - Over the past four quarters, Ovid has beaten consensus EPS estimates three times [13] Comparative Industry Analysis - ImmunityBio (IBRX), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.12 for the same quarter, indicating a year-over-year change of +40% [17] - ImmunityBio's revenues are projected to be $15.69 million, up 39125% from the previous year [17] - The consensus EPS estimate for ImmunityBio has been revised 1.5% lower over the last 30 days, resulting in an Earnings ESP of -2.85% [18]